However, plasma cells were spared in the treatment of lupus with single target CD19 CAR T cells. Additionally, peripheral circulating anti-DNA IgG and IgM autoantibodies remain elevated or increased in treated mice. Here we present the efficacy of BCMA-CD19 compound CAR (cCAR), which target ...
BCMA (B-cell maturation antigen; CD269; TNFRSF17) is selectively over-expressed during the malignant transformation of plasma cells, making it an ideal target for the treatment of multiple myeloma [24]. It is a member of the tumor necrosis factor receptor superfamily and is expressed in norma...
BCMA-directed autologous chimeric antigen receptor T (CAR-T) cells have shown excellent clinical efficacy in relapsed or refractory multiple myeloma (RRMM), however, the current preparation process for autologous CAR-T cells is complicated and costly. Moreover, the upregulation of CD47 expression ha...
BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target immunotherapy. Bispecific CARs are proposed to mitigate these limitations. Methods We constructed...
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial ArticleOpen access20 April 2024 CAR T cell therapies for patients with multiple myeloma Article25 September 2020 Chimeric antigen receptor T cell therapy in multiple myeloma: promise ...
Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CARdoi:10.1007/S12015-021-10251-6Wenli ZhangJia FengAndrew CinquinaQingwen WangHaichan XuQian ZhangLihua SunQi ChenLei XuKevin PinzSpringer US
FIG. 8 contains a series of graphs and flow cytometry plots which illustrate expression of BCMA on MM stem cells. BCMA expression was detected on both the MM plasma cells (CD19-CD138+, grey trace) and on MM stem cells (CD19+CD138−, black trace). ...
tumor cells, and are able to express CAR gens [39]. The main characteristic of CAR-T cells is that they use a CAR against antigen of tumor cells such as BCMA, CD19, CD138 (syndecan-1), Orphan G-protein-coupled receptor class C group 5 member D (GPRC5D) and immunoglobulin kappa ...
Through the promising results of targeting CD19, other targets are also intensively investigated. The first anti-BCMA CAR-T cells were synthesized in 2013 and showed activity in multiple myeloma cell lines [6]. Since then, several BCMA-targeting CAR-T cell constructs have been developed and ...